Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin

R. L. Peugeot, B. A. Lipsky, Thomas Hooton, R. E. Pecoraro

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To assess the safety and efficacy of a ten-day oral course of ofloxacin (400mg 12 hourly) as compared with erythromycin (400mg every 6 hours) for treatment of lower respiratory tract infections, fifty-two adult outpatients with pulmonary infiltrates (pneumonia) or with a cough and purulent sputum (bronchitis) were evaluated. Expectorated sputum specimens were Gram-stained and cultured, and antibody titres to Mycoplasma pneumoniae, Legionella pneumophilia, and in most cases Chlamydia pneumoniae were measured on acute and convalescent serum samples. Patients were evaluated clinically, microbiologically and radiographically three to five days after concluding therapy; the incidence of adverse reactions was monitored throughout the study period. The ofloxacin group (N = 25) was comprised of nineteen patients with pneumonia and six patients with bronchitis. The erythromycin group (N = 27) was comprised of thirteen patients with pneumonia and fourteen patients with bronchitis. All fifty two patients were either clinically improved or cured after therapy. Microbiological cure was documented in all fourteen cases (27%) in which causative pathogens were identified. Clinical cure was achieved with ofloxacin in 68% of patients with pneumonia and in 83% of patients with bronchitis, while clinical cure with erythromycin was achieved in 46% of patients with pneumonia and 54% of patients with bronchitis. Adverse reactions (mostly mild gastrointestinal or central nervous system symptoms) were reported by eight patients receiving ofloxacin and four patients receiving erythromycin. While the types of adverse effects were similar, ofloxacin showed a trend toward a higher rate of cure than erythromycin. Ofloxacin is a promising new antibiotic for the treatment of acute lower respiratory infections.

Original languageEnglish
Pages (from-to)253-257
Number of pages5
JournalDrugs under Experimental and Clinical Research
Volume17
Issue number5
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Ofloxacin
Erythromycin
Respiratory Tract Infections
Outpatients
Bronchitis
Pneumonia
Therapeutics
Sputum
Legionella
Chlamydophila pneumoniae
Mycoplasma pneumoniae
Cough
Central Nervous System

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Cite this

Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin. / Peugeot, R. L.; Lipsky, B. A.; Hooton, Thomas; Pecoraro, R. E.

In: Drugs under Experimental and Clinical Research, Vol. 17, No. 5, 01.01.1991, p. 253-257.

Research output: Contribution to journalArticle

@article{8e16406fef0442e3a4287536fa35653d,
title = "Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin",
abstract = "To assess the safety and efficacy of a ten-day oral course of ofloxacin (400mg 12 hourly) as compared with erythromycin (400mg every 6 hours) for treatment of lower respiratory tract infections, fifty-two adult outpatients with pulmonary infiltrates (pneumonia) or with a cough and purulent sputum (bronchitis) were evaluated. Expectorated sputum specimens were Gram-stained and cultured, and antibody titres to Mycoplasma pneumoniae, Legionella pneumophilia, and in most cases Chlamydia pneumoniae were measured on acute and convalescent serum samples. Patients were evaluated clinically, microbiologically and radiographically three to five days after concluding therapy; the incidence of adverse reactions was monitored throughout the study period. The ofloxacin group (N = 25) was comprised of nineteen patients with pneumonia and six patients with bronchitis. The erythromycin group (N = 27) was comprised of thirteen patients with pneumonia and fourteen patients with bronchitis. All fifty two patients were either clinically improved or cured after therapy. Microbiological cure was documented in all fourteen cases (27{\%}) in which causative pathogens were identified. Clinical cure was achieved with ofloxacin in 68{\%} of patients with pneumonia and in 83{\%} of patients with bronchitis, while clinical cure with erythromycin was achieved in 46{\%} of patients with pneumonia and 54{\%} of patients with bronchitis. Adverse reactions (mostly mild gastrointestinal or central nervous system symptoms) were reported by eight patients receiving ofloxacin and four patients receiving erythromycin. While the types of adverse effects were similar, ofloxacin showed a trend toward a higher rate of cure than erythromycin. Ofloxacin is a promising new antibiotic for the treatment of acute lower respiratory infections.",
author = "Peugeot, {R. L.} and Lipsky, {B. A.} and Thomas Hooton and Pecoraro, {R. E.}",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "17",
pages = "253--257",
journal = "Drugs under Experimental and Clinical Research",
issn = "0378-6501",
publisher = "Bioscience Ediprint Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin

AU - Peugeot, R. L.

AU - Lipsky, B. A.

AU - Hooton, Thomas

AU - Pecoraro, R. E.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - To assess the safety and efficacy of a ten-day oral course of ofloxacin (400mg 12 hourly) as compared with erythromycin (400mg every 6 hours) for treatment of lower respiratory tract infections, fifty-two adult outpatients with pulmonary infiltrates (pneumonia) or with a cough and purulent sputum (bronchitis) were evaluated. Expectorated sputum specimens were Gram-stained and cultured, and antibody titres to Mycoplasma pneumoniae, Legionella pneumophilia, and in most cases Chlamydia pneumoniae were measured on acute and convalescent serum samples. Patients were evaluated clinically, microbiologically and radiographically three to five days after concluding therapy; the incidence of adverse reactions was monitored throughout the study period. The ofloxacin group (N = 25) was comprised of nineteen patients with pneumonia and six patients with bronchitis. The erythromycin group (N = 27) was comprised of thirteen patients with pneumonia and fourteen patients with bronchitis. All fifty two patients were either clinically improved or cured after therapy. Microbiological cure was documented in all fourteen cases (27%) in which causative pathogens were identified. Clinical cure was achieved with ofloxacin in 68% of patients with pneumonia and in 83% of patients with bronchitis, while clinical cure with erythromycin was achieved in 46% of patients with pneumonia and 54% of patients with bronchitis. Adverse reactions (mostly mild gastrointestinal or central nervous system symptoms) were reported by eight patients receiving ofloxacin and four patients receiving erythromycin. While the types of adverse effects were similar, ofloxacin showed a trend toward a higher rate of cure than erythromycin. Ofloxacin is a promising new antibiotic for the treatment of acute lower respiratory infections.

AB - To assess the safety and efficacy of a ten-day oral course of ofloxacin (400mg 12 hourly) as compared with erythromycin (400mg every 6 hours) for treatment of lower respiratory tract infections, fifty-two adult outpatients with pulmonary infiltrates (pneumonia) or with a cough and purulent sputum (bronchitis) were evaluated. Expectorated sputum specimens were Gram-stained and cultured, and antibody titres to Mycoplasma pneumoniae, Legionella pneumophilia, and in most cases Chlamydia pneumoniae were measured on acute and convalescent serum samples. Patients were evaluated clinically, microbiologically and radiographically three to five days after concluding therapy; the incidence of adverse reactions was monitored throughout the study period. The ofloxacin group (N = 25) was comprised of nineteen patients with pneumonia and six patients with bronchitis. The erythromycin group (N = 27) was comprised of thirteen patients with pneumonia and fourteen patients with bronchitis. All fifty two patients were either clinically improved or cured after therapy. Microbiological cure was documented in all fourteen cases (27%) in which causative pathogens were identified. Clinical cure was achieved with ofloxacin in 68% of patients with pneumonia and in 83% of patients with bronchitis, while clinical cure with erythromycin was achieved in 46% of patients with pneumonia and 54% of patients with bronchitis. Adverse reactions (mostly mild gastrointestinal or central nervous system symptoms) were reported by eight patients receiving ofloxacin and four patients receiving erythromycin. While the types of adverse effects were similar, ofloxacin showed a trend toward a higher rate of cure than erythromycin. Ofloxacin is a promising new antibiotic for the treatment of acute lower respiratory infections.

UR - http://www.scopus.com/inward/record.url?scp=0026012326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026012326&partnerID=8YFLogxK

M3 - Article

C2 - 1756688

AN - SCOPUS:0026012326

VL - 17

SP - 253

EP - 257

JO - Drugs under Experimental and Clinical Research

JF - Drugs under Experimental and Clinical Research

SN - 0378-6501

IS - 5

ER -